Translating Stem Cell Research: Challenges at the Research Frontier

Fink D. W. , “FDA Regulation of Stem Cell-based Products,” Science 324, no. 5935 (2009): 1662–1663.

DiMasi J. A. Hansen R. W. Grabowski H. G. , “The Price of Innovation: New Estimates of Drug Development Costs,” Journal of Health Economics 22, no. 2 (2003): 151–185.

McKneally M. F. , “Ethical Problems in Surgery: Innovation Leading to Unforeseen Complications,” World Journal of Surgery 23 (1999): 786–788; McKneally M. F. Daar A. S. , “Introducing New Technologies: Protecting Subjects of Surgical Innovation and Research,” World Journal of Surgery 27 (2003): 930–935; Agich G. J. , “Ethics and Innovation in Medicine,” Journal of Medical Ethics 27 (2001): 295–296; Reitsma A. M. Moreno J. D. , “Ethical Regulations for Innovative Surgery: The Last Frontier?” Journal of the American College of Surgeons 194 (2002): 792–801; Reitsma A. M. Moreno J. D. , “Ethics of Innovative Surgery: US Surgeons' Definitions, Knowledge, and Attitudes,” Journal of the American College of Surgeons 200 (2005): 103–110.

Lindvall O. Hyun I. , “Medical Innovation Versus Stem Cell Tourism,” Science 324, no. 5935 (2009): 1664–1665.

Cook-Deegan R. , The Gene Wars: Science, Politics and the Human Genome (New York: Norton and Co., 1996).

See Geron , Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy, Press Release, January 23, 2009.

Keirstead H. S. Nistor G. Bernal G. Totoiu M. Cloutier F. Sharp K. Steward O. , “Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cell Transplants Remyelinate and Restore Locomotion after Spinal Cord Injury,” Journal of Neuroscience 25, no. 19 (2005): 4694–705.

See Geron , Geron and FDA Reach Agreement on Clinical Hold, Press Release, October 30, 2009.

Emanuel E. J. Wendler D. Grady C. , “What Makes Clinical Research Ethical?” JAMA 283, no. 20 (2000): 2701–2711.

Moore F. D. , “Three Ethical Revolutions: Ancient Assumptions Remodeled Under Pressure of Transplantation,” Transplantation Proceedings 20, 1 Suppl. 1 (1988): 1061–7; Moore F. D. , “The Desperate Case: CARE (Costs, Applicability, Research, Ethics),” JAMA 261, no. 10 (1989): 1483–1484.

Agrawal M. Emanuel E. J. , “Ethics of Phase I Oncology Studies: Reexamining the Arguments and Data,” JAMA 290, no. 8 (2003): 1075–1082.

Cho M. K. Magnus D. , “Therapeutic Misconception and Stem Cell Research,” Nature Reports Stem Cells (2007).

King N. M. Henderson G. E. Churchill L. R. Davis A. M. Hull S. C. Nelson D. K. Parham-Vetter P.C. Rothschild B. B. Easter M. M. Wilfond B. S. , “Consent Forms and the Therapeutic Misconception: The Example of Gene Transfer Research,” IRB 27 (2005): 1–8.

Kimmelman J. Levenstadt A. , “Elements of Style: Consent Form Language and the Therapeutic Misconception in Phase I Gene Transfer Trials,” Human Gene Therapy 16, no. 4 (2005): 502–508.

Id.

See King , supra note 13.

Please note: The author is a member of the CDHP Advisory Committee and drafted the guidelines concerning clinical trials.